Astra taps new North American CFO; FDA reviews drug's eyelash boost;

> AstraZeneca appointed Graham Baker as its new vice president and CFO of North American operations. Report

> FDA staffers said a glaucoma drug from Allergan appears to make eyelashes longer and fuller, and an advisory committee will assess the safety of that new use at a meeting today. Report

> Pfizer's attempts to settle Nigerian litigation and claims over its 1996 Trovan trial there have been complicated by a fictitious list of victims, newspapers report. Report

> GlaxoSmithKline announced a $250,000 donation to The Carter Center to help Ethiopia launch a program to eliminate lymphatic filariasis. Release

> GSK also announced it would cut the price of its human papillomavirus vaccine Cervarix in South Africa to about $43 per dose from about $67. Report

> Auxilium Pharmaceuticals and CPEX Pharmaceuticals sued Upsher-Smith Laboratories for infringement of CPEX's patent on Testim testosterone gel. Release

> Perrigo settled a patent-infringement lawsuit with Schering-Plough, which will allow Perrigo to launch a generic version of allergy drug Clarinex on July 1, 2012. Release

> FDA staffers said a glaucoma drug from Allergan appears to make eyelashes longer and fuller, and an advisory committee will assess the safety of that new use at a meeting today. Report

> A high dose of the chemo drug daunorubicin, sold under the brand name Cerubidine by Bedford Laboratories, prolonged survival for patients with previously untreated acute myeloid leukemia, preliminary study results show. Report

> Combining a calcium-channel blocker and an ACE inhibitor worked better at preventing heart problems in patients high blood pressure than did a diuretic combined with an ACE inhibitor, a large clinical trial suggests. Report

And Finally... The old adage about the world smiling with you is right, researchers say: Happiness is contagious. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.